Clinical Trials
101 trialsOsimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
STARTRK-2
Hoffmann-La Roche
NIVIPI-Brain
Fundación GECP
T-BRAIN
Maastricht University Medical Center
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
Wake Forest University Health Sciences
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Brigham and Women's Hospital
Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis
M.D. Anderson Cancer Center
REPOSE
MedSIR
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
Memorial Sloan Kettering Cancer Center
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
Tianjin Medical University Cancer Institute and Hospital
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
University of Pittsburgh
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases
Zhejiang Cancer Hospital
Study Assessing QBS72S For Treating Brain Metastases
Stanford University
Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
Sun Yat-sen University
Pembro+Chemo in Brain Mets
University of Kentucky
TROPICAL-1
Latin American Cooperative Oncology Group
Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis
Sun Yat-sen University
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
Fudan University
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Yale University
X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
Fudan University
SPARTA
Apollomics Inc.
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
City of Hope Medical Center
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
Maastricht University Medical Center
MR-Linac Guided Adaptive FSRT for Brain Metastases From Non-small Cell Lung Cancer
Sun Yat-sen University
Better Brain
Sun Yat-sen University
Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
Xiangya Hospital of Central South University
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
British Columbia Cancer Agency
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Fudan University
LungBrain001
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
Centre hospitalier de l'Université de Montréal (CHUM)
STRIDER
Maastricht University Medical Center
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
Taizhou Hospital
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Hoosier Cancer Research Network
HA-WBRT-SIB for Brain Metastasis of Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
PAINT
Albert Einstein College of Medicine
Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
Stanford University
CBC
Second Affiliated Hospital of Nanchang University
Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC
Sun Yat-sen University
ALpha-T
Hoffmann-La Roche
Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
Stanford University
Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC
Sun Yat-sen University
STICk-IM-NSCLC
Duke University
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
Genentech, Inc.
Brigatinib Before Brain Irradiation Trial (B3i Trial)
University of Colorado, Denver
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.
Seoul St. Mary's Hospital
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
Kadmon Corporation, LLC
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center